Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amir Pourghadiri1, Touraj Khosravi-Hafshejani2, H Chih-Ho Hong1

  • 1Faculté de médecine (Pourghadiri); Département de dermatologie et de sciences dermatologiques (Khosravi-Hafshejani, Hong), Université de la Colombie-Britannique, Vancouver, C.-B.

CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|January 22, 2024
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology.

Dermatology and therapy·2026
Same author

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

The British journal of dermatology·2026
Same author

Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis.

Dermatology and therapy·2026
Same author

Prednisone dosage is the primary modifiable risk factor for infection in pemphigus with rituximab treatment: A retrospective analysis of 105 patients.

Journal of the American Academy of Dermatology·2026
Same author

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.

Dermatology and therapy·2026
Same author

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

The Journal of dermatological treatment·2026